Penicillin treatment for patients with Community-Acquired Pneumonia in Denmark: a retrospective cohort study

Gertrud Baunbæk Egelund, Andreas Vestergaard Jensen, Stine Bang Andersen, Pelle Trier Petersen, Bjarne Ørskov Lindhardt, Christian von Plessen, Gernot Rohde, Pernille Ravn, Gertrud Baunbæk Egelund, Andreas Vestergaard Jensen, Stine Bang Andersen, Pelle Trier Petersen, Bjarne Ørskov Lindhardt, Christian von Plessen, Gernot Rohde, Pernille Ravn

Abstract

Background: Community-acquired pneumonia (CAP) is a severe infection, with high mortality. Antibiotic strategies for CAP differ across Europe. The objective of the study was to describe the epidemiology of CAP in Denmark and evaluate the prognosis of patients empirically treated with penicillin-G/V monotherapy.

Methods: Retrospective cohort study including hospitalized patients with x-ray confirmed CAP. We calculated the population-based incidence, reviewed types of empiric antibiotics and duration of antibiotic treatment. We evaluated the association between mortality and treatment with empiric penicillin-G/V using logistic regression analysis.

Results: We included 1320 patients. The incidence of hospitalized CAP was 3.1/1000 inhabitants. Median age was 71 years (IQR; 58-81) and in-hospital mortality was 8%. Median duration of antibiotic treatment was 10 days (IQR; 8-12). In total 45% were treated with penicillin-G/V as empiric monotherapy and they did not have a higher mortality compared to patients treated with broader-spectrum antibiotics (OR 0.92, CI 95% 0.55-1.53).

Conclusion: The duration of treatment exceeded recommendations in European guidelines. Empiric monotherapy with penicillin-G/V was commonly used and not associated with increased mortality in patients with mild to moderate pneumonia. Our results are in agreement with current conservative antibiotic strategy as outlined in the Danish guidelines.

Keywords: Community-acquired pneumonia; Incidence; Penicillin; Prognosis.

Figures

Fig. 1
Fig. 1
Screening of patients for inclusion
Fig. 2
Fig. 2
The incidence of community-acquired pneumonia

References

    1. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–79. doi: 10.1136/thx.2009.129502.
    1. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012;18(Suppl 5):7–14. doi: 10.1111/j.1469-0691.2012.03937.x.
    1. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, Perrier A. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141. doi: 10.1186/cc11447.
    1. Bewick T, Sheppard C, Greenwood S, Slack M, Trotter C, George R, Lim WS. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax. 2012;67(6):540–545. doi: 10.1136/thoraxjnl-2011-201092.
    1. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, McCullers JA, Pavia AT, Edwards KM, Finelli L, CDC EPIC Study Team Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015;373(5):415–427. doi: 10.1056/NEJMoa1500245.
    1. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, Schraeder P, Welte T, Hoeffken G. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64(12):1062–1069. doi: 10.1136/thx.2008.109785.
    1. Zarb P, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): value of a point-prevalence survey of antimicrobial use across Europe. Drugs. 2011;71(6):745–755. doi: 10.2165/11591180-000000000-00000.
    1. Spindler C, Stralin K, Eriksson L, Hjerdt-Goscinski G, Holmberg H, Lidman C, Nilsson A, Ortqvist A, Hedlund J, Community Acquired Pneumonia Working Group of The Swedish Society of Infectious Diseases Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults--Swedish Society of Infectious Diseases 2012. Scand J Infect Dis. 2012;44(12):885–902. doi: 10.3109/00365548.2012.700120.
    1. Huijts SM, van Werkhoven CH, Boersma WG, Buijs J, Buunk G, Compaijen CJ, van Elde LJ, Gisolf JE, van der Kam R, Kluytmans JA, Kuipers BA, Mager JJ, Oppedijk B, Palmen F, Prins JM, van Reemst B, Silbermann MH, van Tiel FH, van der Wall E, van der Werf TS, Bonten MJ. Guideline adherence for empirical treatment of pneumonia and patient outcome. Treating pneumonia in the Netherlands. Neth J Med. 2013;71(10):502–7.
    1. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–E59. doi: 10.1111/j.1469-0691.2011.03672.x.
    1. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA, Pneumonia Guidelines Committee of the BTS Standards of Care Committee BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;Suppl 3:iii1–iii55.
    1. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(3):330–339. doi: 10.1093/cid/cit734.
    1. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O’Grady NP, Bartlett JG, Carratala J, El Solh AA, Ewig S, Fey PD, File TM, Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. doi: 10.1093/cid/ciw353.
    1. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377–382. doi: 10.1136/thorax.58.5.377.
    1. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33(7):1065–1079. doi: 10.1007/s10096-014-2067-1.
    1. Blasi F, Garau J, Medina J, Avila M, McBride K, Ostermann H, REACH study group Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Respir Res. 2013;14:44. doi: 10.1186/1465-9921-14-44.
    1. Kirk O, Glenthoj J, Dragsted UB, Helweg-Larsen J, Aru TM, Benfield TL, Jensen K, Vestbo J, Lundgren JD. Penicillin as empirical therapy for patients hospitalised with community acquired pneumonia at a Danish hospital. Dan Med Bull. 2001;48(2):84–88.
    1. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002;162(9):1059–1064. doi: 10.1001/archinte.162.9.1059.
    1. Sintes H, Sibila O, Waterer G, Chalmers J. Severity assessment tools. In: Chalmers J, Pletz M, Aliberti S, editors. European respiratory monograph; community-acquired pneumonia. European Respiratory Society Publications; 2014:88.
    1. Reissig A, Mempel C, Schumacher U, Copetti R, Gross F, Aliberti S. Microbiological diagnosis and antibiotic therapy in patients with community-acquired pneumonia and acute COPD exacerbation in daily clinical practice: comparison to current guidelines. Lung. 2013;191(3):239–246. doi: 10.1007/s00408-013-9460-x.
    1. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008;68(13):1841–1854. doi: 10.2165/00003495-200868130-00004.
    1. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis. 2011;52(10):1232–1240. doi: 10.1093/cid/cir063.
    1. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007;120(9):783–790. doi: 10.1016/j.amjmed.2007.04.023.
    1. Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K, Competence Network for Community-Acquired Pneumonia study group Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J. 2008;32(1):139–146. doi: 10.1183/09031936.00092507.
    1. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ Study Group CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260(1):93–101. doi: 10.1111/j.1365-2796.2006.01657.x.
    1. Aliberti S, Ramirez J, Cosentini R, Brambilla AM, Zanaboni AM, Rossetti V, Tarsia P, Peyrani P, Piffer F, Blasi F. Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. Respir Med. 2011;105(11):1732–1738. doi: 10.1016/j.rmed.2011.07.006.
    1. Chalmers JD, Mandal P, Singanayagam A, Akram AR, Choudhury G, Short PM, Hill AT. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37(9):1409–1420. doi: 10.1007/s00134-011-2261-x.
    1. Kolditz M, Ewig S, Schutte H, Suttorp N, Welte T, Rohde G, the CAPNETZ study group: Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015;278(2):193–202.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel